News | August 12, 2021
Mangalam Drugs signs tech transfer agreement with Nigerian pharma company
Anti-malaria API facility will be operational in 15-18 months
Anti-malaria API facility will be operational in 15-18 months
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company is eligible for 12 months exclusivity from launch
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The aim is to create new genomics solutions that could combat cancer and advance market access
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Subscribe To Our Newsletter & Stay Updated
